Thermo Fisher Scientific (TMO)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$613.78-0.75%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · TMO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks TMO against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to expand capabilities and market presence by acquiring complementary businesses such as Clario and Solventum's Purification & Filtration business.
Stated as a priority in 4 of last 4 quarters. Management completed the acquisition of Clario Holdings, expected to generate $1.25 billion revenue in 2025, and acquired Solventum's Purification & Filtration business. The company announced $8.875 billion cash purchase price for Clario. The trajectory shows delivering on strategic acquisition growth.
“Completed acquisition of Clario Holdings, Inc.”
“Completed acquisition of Clario, strengthening capabilities.”
“Announced definitive agreement to acquire Clario Holdings, Inc.”
“Entered agreement to acquire Solventum's Purification & Filtration Business.”
Continue executing capital deployment strategy with share repurchases, dividend increases, and disciplined use of debt financing.
Management stated disciplined capital allocation in 4 of last 4 quarters, repurchasing $3.0 billion in 2026-Q1 and $1.0 billion in 2026-Q2, increasing dividends by 10%, and issuing debt to fund acquisitions. The trajectory is delivering consistent capital return to shareholders.
Continue launching high-impact, innovative products across multiple segments to drive organic growth and deepen customer partnerships.
Management emphasized product innovation in 5 of last 5 quarters, launching multiple advanced instruments such as Orbitrap mass spectrometers and Cryo-TEM systems. While specific revenue impact is not quantified, recurring product launches support the growth strategy with steady innovation delivery.
“Launched next-generation Orbitrap platforms with AI-driven analytics.”
Deepen customer relationships through strategic collaborations, innovation hubs, and integrated solutions to accelerate customer success.
Management has consistently emphasized strengthening trusted partner status in 5 of last 5 quarters through innovation hubs and strategic collaborations. While financial impact is qualitative, recurring focus and multiple partnerships indicate ongoing delivery of this priority.
“Opened flagship U.S. Bioprocess Design Center and announced collaboration with Precision Health Research, Singapore.”
Maintain consistent revenue growth, margin expansion, and earnings per share improvement through operational excellence and active management.
Management stated delivering strong financial performance in 6 of last 6 quarters. Revenue grew from $10.36B in 2025-Q1 to $11.99B in 2026-Q2, GAAP diluted EPS increased from $3.98 to $4.68. Operating margins and adjusted EPS also improved. The trajectory is delivering consistent financial growth.
“Second quarter revenue grew 10%, GAAP diluted EPS grew 9%, adjusted EPS grew 13%.”
Over the trailing year it converted 1.13x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Repurchased $1.0 billion of stock during the quarter.”
“Repurchased $3.0 billion of stock and increased dividend by 10%.”
“Returned $3.6 billion of capital to shareholders through buybacks and dividends.”
“Repurchased $2.0 billion of stock and increased dividend by 10%.”
“Launched Thermo Scientific Glacios 3 Cryo-TEM and TSQ Certis triple quadrupole mass spectrometer.”
“Launched Thermo Scientific Helios MX1 Plasma Focused Ion Beam SEM and received FDA approvals for diagnostics.”
“Launched Thermo Scientific Iliad scanning transmission electron microscope and Applied Biosystems MagMAX Sequential DNA/RNA kit.”
“Launched Thermo Scientific Orbitrap Astral Zoom mass spectrometer and expanded DynaDrive single-use bioreactor portfolio.”
“Announced strategic collaborations with NVIDIA and SHL Medical to advance scientific instrumentation and drug product manufacturing.”
“Entered technology alliance with Chan Zuckerberg Institute and strategic collaboration with OpenAI.”
“Announced partnership with National Cancer Institute on myeloMATCH precision medicine trial.”
“Strengthened commercial engine and deepened trusted partner status with customers.”
“First quarter revenue grew 6%, GAAP diluted EPS grew 11%, adjusted EPS grew 6%.”
“Fourth quarter revenue grew 7%, GAAP diluted EPS grew 9%, adjusted EPS grew 8%.”
“Third quarter revenue flat, GAAP diluted EPS $4.25, adjusted EPS $5.28.”
“Second quarter revenue grew 3%, GAAP diluted EPS grew 6%, adjusted EPS flat.”
“First quarter revenue flat, GAAP diluted EPS grew 15%, adjusted EPS grew 1%.”